GlassScriptPhysician profile
Allison C Clark
NPI 1295272938
$2,866.95
in general payments reported to CMS, 2019-2025
25 companies · $29.88 in 2025
The $29.88 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $198 · 2022: $1,203 · 2023: $1,131 · 2024: $306 · 2025: $29.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $527.77 | 2022-2024 | |
| Novo Nordisk INC | $505.83 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $364.49 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.52 | 2022-2023 | |
| Amgen INC. | $180.85 | 2021-2023 | Repatha, Otezla |
| Lilly USA, LLC | $174.20 | 2021-2023 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $163.01 | 2021-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $84.45 | 2022-2023 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.69 | 2022-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $73.98 | 2021-2022 | |
| Masimo Corporation | $71.76 | 2022 | |
| Exact Sciences Corporation | $56.98 | 2023 | Cologuard Collection Kit |
| Antares Pharma, INC. | $53.37 | 2022-2024 | Xyosted |
| Amarin Pharma, INC. | $46.29 | 2022 | |
| Janssen Pharmaceuticals, INC | $45.20 | 2022-2023 | Xarelto, Spravato |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $44.74 | 2023 | Quviviq |
| Abbott Laboratories | $41.29 | 2021-2023 | Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $34.42 | 2022 | |
| Axsome Therapeutics, INC. | $30.33 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $24.84 | 2022 | |
| Qiagen, LLC | $22.49 | 2022 | |
| Evoke Pharma, INC. | $14.81 | 2022 | |
| Tris Pharma INC | $13.55 | 2023 | Dyanavel Xr |
| Philips North America LLC | $13.09 | 2023 | |
| Vistapharm, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.